According to an announcement from Tianjin Development Holdings Limited (Stock Code: 882), its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd., recorded total operating income of RMB1,007,280,440.26 for the nine months ended 30 September 2025, compared with RMB1,023,773,647.92 for the same period last year. During the same timeframe, total operating costs reached RMB871,042,976.72, compared with RMB903,119,117.83 in the previous year.

Operating profit stood at RMB446,001,766.23, while total profit came in at RMB433,014,784.98. Lisheng Pharmaceutical reported a net profit of RMB374,284,895.92, up from RMB168,334,446.76. Earnings per share were RMB1.44, compared with RMB0.66 in the corresponding period of 2024.

As of 30 September 2025, Lisheng Pharmaceutical’s total assets amounted to RMB5,921,182,710.88, and total liabilities were RMB917,849,370.11. Owners’ equity reached RMB5,003,333,340.77. The company’s shares are listed on the Shenzhen Stock Exchange, and approximately 34.11% of its issued share capital is indirectly held by Tianjin Development Holdings Limited.